In people with type 2 diabetes sarcopenia is associated with the incidence of cardiovascular disease: a prospective cohort study from the UK Biobank

Boonpor, J., Pell, J. P. , Ho, F. K., Celis-Morales, C. and Gray, S. R. (2023) In people with type 2 diabetes sarcopenia is associated with the incidence of cardiovascular disease: a prospective cohort study from the UK Biobank. Diabetes, Obesity and Metabolism, (doi: 10.1111/dom.15338) (PMID:37881162) (Early Online Publication)

[img] Text
299816_Suppl.pdf - Accepted Version

532kB
[img] Text
299816.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

711kB

Abstract

Aim To investigate the association of sarcopenia with cardiovascular disease (CVD) incidence in people with type 2 diabetes. Materials and Methods A prospective cohort study with 11 974 White European UK Biobank participants with type 2 diabetes, aged 40-70 years, included. Sarcopenia was defined based on the European Working Group on Sarcopenia in Older People as either non-sarcopenic or sarcopenic. Outcomes included CVD, stroke, heart failure (HF) and myocardial infarction (MI). The association between sarcopenia and the incidence of outcomes was investigated using Cox proportional hazard models adjusted for sociodemographic and lifestyle factors. The rate advancement period was used to estimate the time period by which CVD is advanced because of sarcopenia. Results Over a median follow-up of 10.7 years, 1957 participants developed CVDs: 373 had a stroke, 307 had an MI and 742 developed HF. Compared with non-sarcopenia, those with sarcopenia had higher risks of CVD (HR 1.89 [95% CI 1.61; 2.21]), HF (HR 2.59 [95% CI 2.12; 3.18]), stroke (HR 1.90 [95% CI 1.38; 2.63]), and MI (HR 1.56 [95% CI 1.04; 2.33]) after adjustment for all covariates. Those with sarcopenia had CVD incidence rates equivalent to those without sarcopenia who were 14.5 years older. Similar results were found for stroke, HF and MI. Conclusions In people with type 2 diabetes, sarcopenia increased the risk of developing CVD, which might occur earlier than in those without sarcopenia. Therefore, sarcopenia screening and prevention in patients with type 2 diabetes may be useful to prevent the complications of CVD.

Item Type:Articles
Additional Information:This research has been conducted using the UK Biobank resource under application number 7155. UK Biobank was established by the Wellcome Trust; Medical Research Council; Department of Health, Scottish Government; and the Northwest Regional Development Agency. It has also received funding from the Welsh Assembly Government and the British Heart Foundation. J.B. receives financial support from the Royal Thai Government Scholarship for her PhD.
Keywords:Gait, hand strength, heart diseases, muscle mass, type 2 diabetes mellitus, skeleton muscle.
Status:Early Online Publication
Refereed:Yes
Glasgow Author(s) Enlighten ID:Celis, Dr Carlos and Pell, Professor Jill and Gray, Professor Stuart and Ho, Dr Frederick and Boonpor, Jirapitcha
Authors: Boonpor, J., Pell, J. P., Ho, F. K., Celis-Morales, C., and Gray, S. R.
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Public Health
Journal Name:Diabetes, Obesity and Metabolism
Publisher:Wiley
ISSN:1462-8902
ISSN (Online):1463-1326
Published Online:26 October 2023
Copyright Holders:Copyright: © 2023 The Authors
First Published:First published in Diabetes, Obesity and Metabolism 2023
Publisher Policy:Reproduced under a Creative Commons licence

University Staff: Request a correction | Enlighten Editors: Update this record